Q2 FY2026 EarningsQ2 FY2026 results significantly exceeded consensus expectations across the top and bottom lines. Total revenue reached $25.1M vs. the $14.9M expected, driven by the rapid commercial adoption of PALSONIFY which generated $24.0M in net product revenue. GAAP EPS was -$1.14, beating the consensus mean of -$1.21. On July 6, 2026, the company entered into a definitive agreement to be acquired by Vertex Pharmaceuticals for approximately $10.0 billion, leading to the withdrawal of all future guidance.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Crinetics Pharmaceuticals(CRNX) the Revenue is 25.12 M (+2336%), Beat estimate;the EBIT is -132.46 M (-2.59%), Beat estimate;the EPS is -1.14 (+7.32%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B2336.28%
0.01B1342.32%
+0.01B993.96%
EBITExceed expectations
-0.13B2.59%
-0.13B3.55%
+0.00B0.96%
EPSExceed expectations
-1.147.32%
-1.2061.96%
+0.06605.36%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf